Genextra S.p.a. - Net Worth and Insider Trading

Genextra S.p.a. Net Worth

The estimated net worth of Genextra S.p.a. is at least $76 Million dollars as of 2024-07-17. Genextra S.p.a. is the 10% Owner of Intercept Pharmaceuticals Inc and owns about 4,000,000 shares of Intercept Pharmaceuticals Inc (ICPT) stock worth over $76 Million. Details can be seen in Genextra S.p.a.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Genextra S.p.a. has not made any transactions after 2020-08-17 and currently still holds the listed stock(s).

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Genextra S.p.a.


Genextra S.p.a. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Genextra S.p.a. owns 1 companies in total, including Intercept Pharmaceuticals Inc (ICPT) .

Click here to see the complete history of Genextra S.p.a.’s form 4 insider trades.

Insider Ownership Summary of Genextra S.p.a.

Ticker Comapny Transaction Date Type of Owner
ICPT Intercept Pharmaceuticals Inc 2020-08-17 10 percent owner

Genextra S.p.a. Latest Holdings Summary

Genextra S.p.a. currently owns a total of 1 stock. Genextra S.p.a. owns 4,000,000 shares of Intercept Pharmaceuticals Inc (ICPT) as of August 17, 2020, with a value of $76 Million.

Latest Holdings of Genextra S.p.a.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ICPT Intercept Pharmaceuticals Inc 2020-08-17 4,000,000 19.00 76,000,000

Holding Weightings of Genextra S.p.a.

Genextra S.p.a. Form 4 Trading Tracker

According to the SEC Form 4 filings, Genextra S.p.a. has made a total of 2 transactions in Intercept Pharmaceuticals Inc (ICPT) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Intercept Pharmaceuticals Inc is the sale of 1,500,000 shares on August 17, 2020, which brought Genextra S.p.a. around $71 Million.

Insider Trading History of Genextra S.p.a.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Genextra S.p.a. Trading Performance

GuruFocus tracks the stock performance after each of Genextra S.p.a.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Genextra S.p.a. is 36.02%. GuruFocus also compares Genextra S.p.a.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Genextra S.p.a. within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Genextra S.p.a.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Genextra S.p.a.

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return to S&P 500(%) 0.75 LIMIT LIMIT LIMIT LIMIT LIMIT

Genextra S.p.a. Ownership Network

Ownership Network List of Genextra S.p.a.

No Data

Ownership Network Relation of Genextra S.p.a.

Insider Network Chart

Genextra S.p.a. Owned Company Details

What does Intercept Pharmaceuticals Inc do?

Who are the key executives at Intercept Pharmaceuticals Inc?

Genextra S.p.a. is the 10 percent owner of Intercept Pharmaceuticals Inc. Other key executives at Intercept Pharmaceuticals Inc include EVP & Chief Financial Officer Andrew Saik , President & R&D and CMO M Michelle Berrey , and Chief Accounting Officer Rocco Venezia .

Intercept Pharmaceuticals Inc (ICPT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Intercept Pharmaceuticals Inc (ICPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Intercept Pharmaceuticals Inc (ICPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Intercept Pharmaceuticals Inc (ICPT)'s detailed insider trading history can be found in Insider Trading Tracker table.


Intercept Pharmaceuticals Inc Insider Transactions

No Available Data

Genextra S.p.a. Mailing Address

Above is the net worth, insider trading, and ownership report for Genextra S.p.a.. You might contact Genextra S.p.a. via mailing address: Via G. De Grassi, 11, Milan L6 20123.

Discussions on Genextra S.p.a.

No discussions yet.